Structure Therapeutics Inc. (NASDAQ:GPCR) Receives Average Recommendation of “Buy” from Analysts

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) have been given a consensus recommendation of “Buy” by the seven research firms that are covering the company, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy recommendation. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $86.50.

Several equities analysts recently commented on the company. JMP Securities reiterated a “market outperform” rating and issued a $91.00 price objective on shares of Structure Therapeutics in a research note on Wednesday. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price target on shares of Structure Therapeutics in a research report on Thursday. Morgan Stanley started coverage on Structure Therapeutics in a report on Monday, September 23rd. They issued an “overweight” rating and a $118.00 price objective for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $65.00 price objective on shares of Structure Therapeutics in a report on Monday, September 23rd.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in GPCR. Wellington Management Group LLP raised its holdings in shares of Structure Therapeutics by 2.9% during the 3rd quarter. Wellington Management Group LLP now owns 7,769,771 shares of the company’s stock valued at $341,015,000 after buying an additional 221,851 shares in the last quarter. FMR LLC raised its stake in shares of Structure Therapeutics by 6.7% during the third quarter. FMR LLC now owns 6,128,444 shares of the company’s stock worth $268,977,000 after acquiring an additional 383,635 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Structure Therapeutics by 18.0% in the 3rd quarter. Janus Henderson Group PLC now owns 3,956,878 shares of the company’s stock worth $173,623,000 after acquiring an additional 602,609 shares during the last quarter. Driehaus Capital Management LLC lifted its holdings in shares of Structure Therapeutics by 3.5% in the 2nd quarter. Driehaus Capital Management LLC now owns 2,577,136 shares of the company’s stock worth $101,204,000 after acquiring an additional 86,833 shares during the last quarter. Finally, Federated Hermes Inc. boosted its stake in shares of Structure Therapeutics by 6.6% in the 2nd quarter. Federated Hermes Inc. now owns 2,407,206 shares of the company’s stock valued at $94,531,000 after purchasing an additional 150,000 shares in the last quarter. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Structure Therapeutics Stock Performance

GPCR opened at $29.97 on Friday. Structure Therapeutics has a fifty-two week low of $26.23 and a fifty-two week high of $62.74. The firm has a 50-day moving average of $35.53 and a 200 day moving average of $39.03. The firm has a market cap of $1.72 billion, a P/E ratio of -40.50 and a beta of -3.41.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.